Bittensor is not just a crypto narrative anymore.

Metanova Labs is running live drug discovery competitions on Subnet 68 right now:
- 11 million small molecules screened across 9 targets.
- 4,200 nanobody designs targeting PD-L1.
- 63 unique algorithms searching chemical space.
This is not a whitepaper.
This is not a roadmap slide.
This is active pharmaceutical R&D running on a decentralized incentive network.
The reason this matters is that early-stage drug selection is where pharma bleeds the most. Wrong compound picked at step one means tens of millions wasted on synthesis, animal trials, and clinical phases that go nowhere.
NOVA fixes step one using three layers working in a closed loop:
1) Human insight defines the problem.
2) AI agents run the research and orchestration.
3) Machine learning predicts and explores at scale.
No other group is combining all three in one discovery loop. That is the edge.
$TAO is not competing with other L1s.
It is competing with Pfizer’s R&D budget.
The people who understand that early will not need to explain it later.